Literature DB >> 28100096

Targeting therapy-resistant cancer stem cells by hyperthermia.

A L Oei1,2, L E M Vriend3, P M Krawczyk3, M R Horsman4, N A P Franken1,2, J Crezee2.   

Abstract

Eradication of all malignant cells is the ultimate but challenging goal of anti-cancer treatment; most traditional clinically-available approaches fail because there are cells in a tumour that either escape therapy or become therapy-resistant. A subpopulation of cancer cells, the cancer stem cells (CSCs), is considered to be of particular significance for tumour initiation, progression and metastasis. CSCs are considered in particular to be therapy-resistant and may drive disease recurrence, which positions CSCs in the focus of anti-cancer research, but successful CSC-targeting therapies are limited. Here, we argue that hyperthermia - a therapeutic approach based on local heating of a tumour - is potentially beneficial for targeting CSCs in solid tumours. First, hyperthermia has been described to target cells in hypoxic and nutrient-deprived tumour areas where CSCs reside and ionising radiation and chemotherapy are least effective. Second, hyperthermia can modify factors that are essential for tumour survival and growth, such as the microenvironment, immune responses, vascularisation and oxygen supply. Third, hyperthermia targets multiple DNA repair pathways, which are generally upregulated in CSCs and protect them from DNA-damaging agents. Addition of hyperthermia to the therapeutic armamentarium of oncologists may thus be a promising strategy to eliminate therapy-escaping and -resistant CSCs.

Entities:  

Keywords:  Hyperthermia; cancer stem cells; hypoxia; microenvironmental niche; radiation and chemotherapy resistance

Year:  2017        PMID: 28100096     DOI: 10.1080/02656736.2017.1279757

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  23 in total

Review 1.  Ultrasound Hyperthermia Technology for Radiosensitization.

Authors:  Lifei Zhu; Michael B Altman; Andrei Laszlo; William Straube; Imran Zoberi; Dennis E Hallahan; Hong Chen
Journal:  Ultrasound Med Biol       Date:  2019-02-14       Impact factor: 2.998

2.  Thermal Therapy Approaches for Treatment of Brain Tumors in Animals and Humans.

Authors:  A L Bredlau; M A McCrackin; Anjan Motamarry; Kris Helke; Chao Chen; Ann-Marie Broome; Dieter Haemmerich
Journal:  Crit Rev Biomed Eng       Date:  2016

Review 3.  Novel ablation methods for treatment of gliomas.

Authors:  Brittanie Partridge; John H Rossmeisl; Alexandra M Kaloss; Erwin Kristobal Gudenschwager Basso; Michelle H Theus
Journal:  J Neurosci Methods       Date:  2020-02-14       Impact factor: 2.390

Review 4.  Molecular Chaperones in Cancer Stem Cells: Determinants of Stemness and Potential Targets for Antitumor Therapy.

Authors:  Alexander Kabakov; Anna Yakimova; Olga Matchuk
Journal:  Cells       Date:  2020-04-06       Impact factor: 6.600

Review 5.  New physical approaches to treat cancer stem cells: a review.

Authors:  H Ghaffari; J Beik; A Talebi; S R Mahdavi; H Abdollahi
Journal:  Clin Transl Oncol       Date:  2018-06-04       Impact factor: 3.405

6.  Neoadjuvant chemotherapy followed by fast-track cytoreductive surgery plus short-course hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: preliminary results of a promising all-in-one approach.

Authors:  Thales Paulo Batista; Vandré Cabral G Carneiro; Rodrigo Tancredi; Ana Ligia Bezerra Teles; Levon Badiglian-Filho; Cristiano Souza Leão
Journal:  Cancer Manag Res       Date:  2017-12-13       Impact factor: 3.989

Review 7.  The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer.

Authors:  Dimakatso Alice Senthebane; Arielle Rowe; Nicholas Ekow Thomford; Hendrina Shipanga; Daniella Munro; Mohammad A M Al Mazeedi; Hashim A M Almazyadi; Karlien Kallmeyer; Collet Dandara; Michael S Pepper; M Iqbal Parker; Kevin Dzobo
Journal:  Int J Mol Sci       Date:  2017-07-21       Impact factor: 5.923

8.  Reirradiation + hyperthermia for recurrent breast cancer en cuirasse.

Authors:  Sabine Oldenborg; Coen R N Rasch; Rob van Os; Yoka H Kusumanto; Bing S Oei; Jack L Venselaar; Martijn W Heymans; Paul J Zum Vörde Sive Vörding; Hans Crezee; Geertjan van Tienhoven
Journal:  Strahlenther Onkol       Date:  2017-12-20       Impact factor: 3.621

9.  Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.

Authors:  Jing Luo; Xinchi Dai; Hua Hu; Jie Chen; Lujun Zhao; Changyong Yang; Jifeng Sun; Lianmin Zhang; Qian Wang; Shilei Xu; Yue Xu; Ningbo Liu; Guoguang Ying; Ping Wang
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-30       Impact factor: 4.553

10.  Magnetic hyperthermia of breast cancer cells and MRI relaxometry with dendrimer-coated iron-oxide nanoparticles.

Authors:  Marzieh Salimi; Saeed Sarkar; Reza Saber; Hamid Delavari; Ali Mohammad Alizadeh; Hendrik Thijmen Mulder
Journal:  Cancer Nanotechnol       Date:  2018-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.